Transurethral plasma vaporization of the prostate: 3‐month functional outcome and complications
Study Type – Therapy (multi‐centre cohort) Level of Evidence 2b OBJECTIVE To evaluate the early functional outcomes of transurethral plasma vaporization of the prostate (TUVis) in a multicentre study. PATIENTS AND METHODS A prospective multicentre observational study was conducted in eight urology d...
Gespeichert in:
| Veröffentlicht in: | BJU international 2012-08, Vol.110 (4), p.555-560 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 560 |
|---|---|
| container_issue | 4 |
| container_start_page | 555 |
| container_title | BJU international |
| container_volume | 110 |
| creator | Robert, Grégoire Descazeaud, Aurélien Delongchamps, Nicolas Barry Ballereau, Charles Haillot, Olivier Saussine, Christian Kleinklauss, François Pasticier, Gilles Azzouzi, Abdel‐Rahmène Lukacs, Bertrand Dumonceau, Olivier Fourmarier, Marc De La Taille, Alexandre Devonec, Marian |
| description | Study Type – Therapy (multi‐centre cohort)
Level of Evidence 2b
OBJECTIVE
To evaluate the early functional outcomes of transurethral plasma vaporization of the prostate (TUVis) in a multicentre study.
PATIENTS AND METHODS
A prospective multicentre observational study was conducted in eight urology departments. The inclusion criterion was benign prostatic hyperplasia (BPH) requiring surgical treatment. Patients on anti‐coagulant therapy were not excluded. The TUVis procedure was performed according to a classic transurethral resection of the prostate (TURP) scheme following the manufacturer’s recommendations. We evaluated subjective functional outcome using self‐questionnaires (International Prostate Symptom Score [IPSS] and five‐item International Index of Erectile Function [IIEF‐5]) and objective criteria (prostate volume, prostate‐specific antigen [PSA], uroflowmetry, post residual volume) at baseline and at 1‐ and 3‐month follow‐ups. All types of complications were systematically recorded.
RESULTS
Despite 52% of patients receiving anticoagulant therapy before surgery, we reported only 3% with haemorrhagic complications, no blood transfusion, a mean catheterization time of 44 h and a mean postoperative stay of 2.9 nights. No significant change in irrigation time, catheter time or hospital stay was observed in patients with or without anticoagulant therapy. The IPSS and bother scores significantly decreased after the 3‐month follow‐up (57% and 59%, respectively), but the average remaining prostate volume was 29 cc and the tissue ablation rate was only 0.5 cc/min. Three major complications occurred, consisting of two urinary fistulas and one partial bladder coagulation.
CONCLUSIONS
The TUVis procedure has a proven fast postoperative recovery time, good short‐term functional outcome and good haemostatic efficiency. However, the tissue ablation rate was lower than expected and we encountered three major complications, the mechanisms of which remain unclear. Considering the high energy level required to create the plasma effect, the generator, cable and resectoscope must be carefully checked before each procedure. |
| doi_str_mv | 10.1111/j.1464-410X.2010.09806.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1080615290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2975490611</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4276-bbe067f0ec33e3ebde6b5dbf7ea46b6db4c0f8407c6b4d227e2af2561d3272e03</originalsourceid><addsrcrecordid>eNqNkc1qGzEQx0VoiFM3rxAEodCLHX2t1i70kIY2Hxh6SaA3IWlHeM3uaiPt5uuUR-gz9kmqtR0HcqouGka_Gc38_whhSqY0ndPVlAopJoKS31NGUpbMZ0ROH_fQ4e7hw2tM5nKEPsa4IiQlZHaARowSIZiYHSJ9E3QT-wDdMugKt5WOtcb3uvWhfNZd6RvsHe6WgNvgY6c7-Ir535c_tW-6JXZ9YwcmVfq-s74GrJsCp6CtSrsuj5_QvtNVhKPtPUa3P3_cnF9OFr8urs7PFhMrWC4nxgCRuSNgOQcOpgBpssK4HLSQRhZGWOJmguRWGlEwlgPTjmWSFpzlDAgfoy-bvmnQux5ip-oyWqgq3YDvo6IkSUQzNh_Qk3foyvchbZEonnGezTNCEzXbUDZtHgM41Yay1uEptVKDDWqlBoXVoLYabFBrG9RjKj3eftCbGopd4avuCfi8BXS0unLJBFvGN04yLrI0yRh923APZQVP_z2A-n59O0T8H8VopcI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1353359501</pqid></control><display><type>article</type><title>Transurethral plasma vaporization of the prostate: 3‐month functional outcome and complications</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Robert, Grégoire ; Descazeaud, Aurélien ; Delongchamps, Nicolas Barry ; Ballereau, Charles ; Haillot, Olivier ; Saussine, Christian ; Kleinklauss, François ; Pasticier, Gilles ; Azzouzi, Abdel‐Rahmène ; Lukacs, Bertrand ; Dumonceau, Olivier ; Fourmarier, Marc ; De La Taille, Alexandre ; Devonec, Marian</creator><creatorcontrib>Robert, Grégoire ; Descazeaud, Aurélien ; Delongchamps, Nicolas Barry ; Ballereau, Charles ; Haillot, Olivier ; Saussine, Christian ; Kleinklauss, François ; Pasticier, Gilles ; Azzouzi, Abdel‐Rahmène ; Lukacs, Bertrand ; Dumonceau, Olivier ; Fourmarier, Marc ; De La Taille, Alexandre ; Devonec, Marian</creatorcontrib><description>Study Type – Therapy (multi‐centre cohort)
Level of Evidence 2b
OBJECTIVE
To evaluate the early functional outcomes of transurethral plasma vaporization of the prostate (TUVis) in a multicentre study.
PATIENTS AND METHODS
A prospective multicentre observational study was conducted in eight urology departments. The inclusion criterion was benign prostatic hyperplasia (BPH) requiring surgical treatment. Patients on anti‐coagulant therapy were not excluded. The TUVis procedure was performed according to a classic transurethral resection of the prostate (TURP) scheme following the manufacturer’s recommendations. We evaluated subjective functional outcome using self‐questionnaires (International Prostate Symptom Score [IPSS] and five‐item International Index of Erectile Function [IIEF‐5]) and objective criteria (prostate volume, prostate‐specific antigen [PSA], uroflowmetry, post residual volume) at baseline and at 1‐ and 3‐month follow‐ups. All types of complications were systematically recorded.
RESULTS
Despite 52% of patients receiving anticoagulant therapy before surgery, we reported only 3% with haemorrhagic complications, no blood transfusion, a mean catheterization time of 44 h and a mean postoperative stay of 2.9 nights. No significant change in irrigation time, catheter time or hospital stay was observed in patients with or without anticoagulant therapy. The IPSS and bother scores significantly decreased after the 3‐month follow‐up (57% and 59%, respectively), but the average remaining prostate volume was 29 cc and the tissue ablation rate was only 0.5 cc/min. Three major complications occurred, consisting of two urinary fistulas and one partial bladder coagulation.
CONCLUSIONS
The TUVis procedure has a proven fast postoperative recovery time, good short‐term functional outcome and good haemostatic efficiency. However, the tissue ablation rate was lower than expected and we encountered three major complications, the mechanisms of which remain unclear. Considering the high energy level required to create the plasma effect, the generator, cable and resectoscope must be carefully checked before each procedure.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/j.1464-410X.2010.09806.x</identifier><identifier>PMID: 21044248</identifier><identifier>CODEN: BJINFO</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Aged, 80 and over ; benign prostatic hyperplasia ; Biological and medical sciences ; Cutaneous Fistula - etiology ; Electrocoagulation - methods ; endourology ; Genital system. Mammary gland ; Humans ; Length of Stay ; Lower Urinary Tract Symptoms - etiology ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; plasma vaporization ; Postoperative Complications - etiology ; Prospective Studies ; Prostatic Hyperplasia - surgery ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Transurethral Resection of Prostate - methods ; Treatment Outcome ; Tumors of the urinary system ; TURP ; TUVIS ; Urethral Diseases - etiology ; urethro‐cutaneous fistula ; Urinary Fistula - etiology ; Urinary tract. Prostate gland</subject><ispartof>BJU international, 2012-08, Vol.110 (4), p.555-560</ispartof><rights>2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL</rights><rights>2015 INIST-CNRS</rights><rights>2010 THE AUTHORS. BJU INTERNATIONAL © 2010 BJU INTERNATIONAL.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4276-bbe067f0ec33e3ebde6b5dbf7ea46b6db4c0f8407c6b4d227e2af2561d3272e03</citedby><cites>FETCH-LOGICAL-c4276-bbe067f0ec33e3ebde6b5dbf7ea46b6db4c0f8407c6b4d227e2af2561d3272e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1464-410X.2010.09806.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1464-410X.2010.09806.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26234553$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21044248$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robert, Grégoire</creatorcontrib><creatorcontrib>Descazeaud, Aurélien</creatorcontrib><creatorcontrib>Delongchamps, Nicolas Barry</creatorcontrib><creatorcontrib>Ballereau, Charles</creatorcontrib><creatorcontrib>Haillot, Olivier</creatorcontrib><creatorcontrib>Saussine, Christian</creatorcontrib><creatorcontrib>Kleinklauss, François</creatorcontrib><creatorcontrib>Pasticier, Gilles</creatorcontrib><creatorcontrib>Azzouzi, Abdel‐Rahmène</creatorcontrib><creatorcontrib>Lukacs, Bertrand</creatorcontrib><creatorcontrib>Dumonceau, Olivier</creatorcontrib><creatorcontrib>Fourmarier, Marc</creatorcontrib><creatorcontrib>De La Taille, Alexandre</creatorcontrib><creatorcontrib>Devonec, Marian</creatorcontrib><title>Transurethral plasma vaporization of the prostate: 3‐month functional outcome and complications</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Study Type – Therapy (multi‐centre cohort)
Level of Evidence 2b
OBJECTIVE
To evaluate the early functional outcomes of transurethral plasma vaporization of the prostate (TUVis) in a multicentre study.
PATIENTS AND METHODS
A prospective multicentre observational study was conducted in eight urology departments. The inclusion criterion was benign prostatic hyperplasia (BPH) requiring surgical treatment. Patients on anti‐coagulant therapy were not excluded. The TUVis procedure was performed according to a classic transurethral resection of the prostate (TURP) scheme following the manufacturer’s recommendations. We evaluated subjective functional outcome using self‐questionnaires (International Prostate Symptom Score [IPSS] and five‐item International Index of Erectile Function [IIEF‐5]) and objective criteria (prostate volume, prostate‐specific antigen [PSA], uroflowmetry, post residual volume) at baseline and at 1‐ and 3‐month follow‐ups. All types of complications were systematically recorded.
RESULTS
Despite 52% of patients receiving anticoagulant therapy before surgery, we reported only 3% with haemorrhagic complications, no blood transfusion, a mean catheterization time of 44 h and a mean postoperative stay of 2.9 nights. No significant change in irrigation time, catheter time or hospital stay was observed in patients with or without anticoagulant therapy. The IPSS and bother scores significantly decreased after the 3‐month follow‐up (57% and 59%, respectively), but the average remaining prostate volume was 29 cc and the tissue ablation rate was only 0.5 cc/min. Three major complications occurred, consisting of two urinary fistulas and one partial bladder coagulation.
CONCLUSIONS
The TUVis procedure has a proven fast postoperative recovery time, good short‐term functional outcome and good haemostatic efficiency. However, the tissue ablation rate was lower than expected and we encountered three major complications, the mechanisms of which remain unclear. Considering the high energy level required to create the plasma effect, the generator, cable and resectoscope must be carefully checked before each procedure.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>benign prostatic hyperplasia</subject><subject>Biological and medical sciences</subject><subject>Cutaneous Fistula - etiology</subject><subject>Electrocoagulation - methods</subject><subject>endourology</subject><subject>Genital system. Mammary gland</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>Lower Urinary Tract Symptoms - etiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>plasma vaporization</subject><subject>Postoperative Complications - etiology</subject><subject>Prospective Studies</subject><subject>Prostatic Hyperplasia - surgery</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Transurethral Resection of Prostate - methods</subject><subject>Treatment Outcome</subject><subject>Tumors of the urinary system</subject><subject>TURP</subject><subject>TUVIS</subject><subject>Urethral Diseases - etiology</subject><subject>urethro‐cutaneous fistula</subject><subject>Urinary Fistula - etiology</subject><subject>Urinary tract. Prostate gland</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc1qGzEQx0VoiFM3rxAEodCLHX2t1i70kIY2Hxh6SaA3IWlHeM3uaiPt5uuUR-gz9kmqtR0HcqouGka_Gc38_whhSqY0ndPVlAopJoKS31NGUpbMZ0ROH_fQ4e7hw2tM5nKEPsa4IiQlZHaARowSIZiYHSJ9E3QT-wDdMugKt5WOtcb3uvWhfNZd6RvsHe6WgNvgY6c7-Ir535c_tW-6JXZ9YwcmVfq-s74GrJsCp6CtSrsuj5_QvtNVhKPtPUa3P3_cnF9OFr8urs7PFhMrWC4nxgCRuSNgOQcOpgBpssK4HLSQRhZGWOJmguRWGlEwlgPTjmWSFpzlDAgfoy-bvmnQux5ip-oyWqgq3YDvo6IkSUQzNh_Qk3foyvchbZEonnGezTNCEzXbUDZtHgM41Yay1uEptVKDDWqlBoXVoLYabFBrG9RjKj3eftCbGopd4avuCfi8BXS0unLJBFvGN04yLrI0yRh923APZQVP_z2A-n59O0T8H8VopcI</recordid><startdate>201208</startdate><enddate>201208</enddate><creator>Robert, Grégoire</creator><creator>Descazeaud, Aurélien</creator><creator>Delongchamps, Nicolas Barry</creator><creator>Ballereau, Charles</creator><creator>Haillot, Olivier</creator><creator>Saussine, Christian</creator><creator>Kleinklauss, François</creator><creator>Pasticier, Gilles</creator><creator>Azzouzi, Abdel‐Rahmène</creator><creator>Lukacs, Bertrand</creator><creator>Dumonceau, Olivier</creator><creator>Fourmarier, Marc</creator><creator>De La Taille, Alexandre</creator><creator>Devonec, Marian</creator><general>Blackwell Publishing Ltd</general><general>Wiley-Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>201208</creationdate><title>Transurethral plasma vaporization of the prostate: 3‐month functional outcome and complications</title><author>Robert, Grégoire ; Descazeaud, Aurélien ; Delongchamps, Nicolas Barry ; Ballereau, Charles ; Haillot, Olivier ; Saussine, Christian ; Kleinklauss, François ; Pasticier, Gilles ; Azzouzi, Abdel‐Rahmène ; Lukacs, Bertrand ; Dumonceau, Olivier ; Fourmarier, Marc ; De La Taille, Alexandre ; Devonec, Marian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4276-bbe067f0ec33e3ebde6b5dbf7ea46b6db4c0f8407c6b4d227e2af2561d3272e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>benign prostatic hyperplasia</topic><topic>Biological and medical sciences</topic><topic>Cutaneous Fistula - etiology</topic><topic>Electrocoagulation - methods</topic><topic>endourology</topic><topic>Genital system. Mammary gland</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>Lower Urinary Tract Symptoms - etiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>plasma vaporization</topic><topic>Postoperative Complications - etiology</topic><topic>Prospective Studies</topic><topic>Prostatic Hyperplasia - surgery</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Transurethral Resection of Prostate - methods</topic><topic>Treatment Outcome</topic><topic>Tumors of the urinary system</topic><topic>TURP</topic><topic>TUVIS</topic><topic>Urethral Diseases - etiology</topic><topic>urethro‐cutaneous fistula</topic><topic>Urinary Fistula - etiology</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robert, Grégoire</creatorcontrib><creatorcontrib>Descazeaud, Aurélien</creatorcontrib><creatorcontrib>Delongchamps, Nicolas Barry</creatorcontrib><creatorcontrib>Ballereau, Charles</creatorcontrib><creatorcontrib>Haillot, Olivier</creatorcontrib><creatorcontrib>Saussine, Christian</creatorcontrib><creatorcontrib>Kleinklauss, François</creatorcontrib><creatorcontrib>Pasticier, Gilles</creatorcontrib><creatorcontrib>Azzouzi, Abdel‐Rahmène</creatorcontrib><creatorcontrib>Lukacs, Bertrand</creatorcontrib><creatorcontrib>Dumonceau, Olivier</creatorcontrib><creatorcontrib>Fourmarier, Marc</creatorcontrib><creatorcontrib>De La Taille, Alexandre</creatorcontrib><creatorcontrib>Devonec, Marian</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robert, Grégoire</au><au>Descazeaud, Aurélien</au><au>Delongchamps, Nicolas Barry</au><au>Ballereau, Charles</au><au>Haillot, Olivier</au><au>Saussine, Christian</au><au>Kleinklauss, François</au><au>Pasticier, Gilles</au><au>Azzouzi, Abdel‐Rahmène</au><au>Lukacs, Bertrand</au><au>Dumonceau, Olivier</au><au>Fourmarier, Marc</au><au>De La Taille, Alexandre</au><au>Devonec, Marian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transurethral plasma vaporization of the prostate: 3‐month functional outcome and complications</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2012-08</date><risdate>2012</risdate><volume>110</volume><issue>4</issue><spage>555</spage><epage>560</epage><pages>555-560</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><coden>BJINFO</coden><abstract>Study Type – Therapy (multi‐centre cohort)
Level of Evidence 2b
OBJECTIVE
To evaluate the early functional outcomes of transurethral plasma vaporization of the prostate (TUVis) in a multicentre study.
PATIENTS AND METHODS
A prospective multicentre observational study was conducted in eight urology departments. The inclusion criterion was benign prostatic hyperplasia (BPH) requiring surgical treatment. Patients on anti‐coagulant therapy were not excluded. The TUVis procedure was performed according to a classic transurethral resection of the prostate (TURP) scheme following the manufacturer’s recommendations. We evaluated subjective functional outcome using self‐questionnaires (International Prostate Symptom Score [IPSS] and five‐item International Index of Erectile Function [IIEF‐5]) and objective criteria (prostate volume, prostate‐specific antigen [PSA], uroflowmetry, post residual volume) at baseline and at 1‐ and 3‐month follow‐ups. All types of complications were systematically recorded.
RESULTS
Despite 52% of patients receiving anticoagulant therapy before surgery, we reported only 3% with haemorrhagic complications, no blood transfusion, a mean catheterization time of 44 h and a mean postoperative stay of 2.9 nights. No significant change in irrigation time, catheter time or hospital stay was observed in patients with or without anticoagulant therapy. The IPSS and bother scores significantly decreased after the 3‐month follow‐up (57% and 59%, respectively), but the average remaining prostate volume was 29 cc and the tissue ablation rate was only 0.5 cc/min. Three major complications occurred, consisting of two urinary fistulas and one partial bladder coagulation.
CONCLUSIONS
The TUVis procedure has a proven fast postoperative recovery time, good short‐term functional outcome and good haemostatic efficiency. However, the tissue ablation rate was lower than expected and we encountered three major complications, the mechanisms of which remain unclear. Considering the high energy level required to create the plasma effect, the generator, cable and resectoscope must be carefully checked before each procedure.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21044248</pmid><doi>10.1111/j.1464-410X.2010.09806.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2012-08, Vol.110 (4), p.555-560 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1080615290 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Aged, 80 and over benign prostatic hyperplasia Biological and medical sciences Cutaneous Fistula - etiology Electrocoagulation - methods endourology Genital system. Mammary gland Humans Length of Stay Lower Urinary Tract Symptoms - etiology Male Medical sciences Middle Aged Nephrology. Urinary tract diseases plasma vaporization Postoperative Complications - etiology Prospective Studies Prostatic Hyperplasia - surgery Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Transurethral Resection of Prostate - methods Treatment Outcome Tumors of the urinary system TURP TUVIS Urethral Diseases - etiology urethro‐cutaneous fistula Urinary Fistula - etiology Urinary tract. Prostate gland |
| title | Transurethral plasma vaporization of the prostate: 3‐month functional outcome and complications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T20%3A31%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transurethral%20plasma%20vaporization%20of%20the%20prostate:%203%E2%80%90month%20functional%20outcome%20and%20complications&rft.jtitle=BJU%20international&rft.au=Robert,%20Gr%C3%A9goire&rft.date=2012-08&rft.volume=110&rft.issue=4&rft.spage=555&rft.epage=560&rft.pages=555-560&rft.issn=1464-4096&rft.eissn=1464-410X&rft.coden=BJINFO&rft_id=info:doi/10.1111/j.1464-410X.2010.09806.x&rft_dat=%3Cproquest_cross%3E2975490611%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1353359501&rft_id=info:pmid/21044248&rfr_iscdi=true |